572 Long term treatment outcome after Pelvic exenterations for recurrent gynaecological cancers

PN Rema, S Sambasivan, A Nath, S Ranjith J, A Mathew
2021 Cervical cancer   unpublished
58.3%) patients deceased and 2 (16.7%) were alive without evidence of cancer. Conclusion* in our series, bevacizumab had the expected outcomes and safety profile. Nevertheless, multicentric studies are needed to evaluate the true added value of bevacizumab to P-CT in ACC treatment in real-world practice and to identify predictive factors.
doi:10.1136/ijgc-2021-esgo.45 fatcat:hoj7tckiyndqtkhxlvvznkcqyy